Clinical Scorecard: Semaglutide outcomes in Japanese patients with MASH align with results from the overall ESSENCE trial population

At a Glance

Key Highlights

• Among 116 Japanese participants, MASH resolution without fibrosis worsening occurred in 63.1% with semaglutide and 36.8% with placebo.

• The Japanese subgroup’s MASH-resolution rates were similar to those in the overall ESSENCE population: 62.9% with semaglutide and 34.3% with placebo.

• Semaglutide numerically favored MASH resolution in the BMI <27 kg/m² subgroup (57.1% vs 26.7%).

• Percentage weight loss was comparable in Japanese and overall active-treatment participants (11.4% vs 10.5%), despite lower baseline body weight in the Japanese subgroup.

• The subgroup was small; efficacy in non-obese patients with BMI <25 kg/m² and effects on liver-related events remain unestablished.

Guideline-Based Recommendations

Diagnosis

• The ESSENCE subgroup analysis included Japanese adults with biopsy-confirmed MASH and moderate-to-advanced fibrosis (F2–F3), without cirrhosis.

Management

• The article reports semaglutide approval in Japan for non-cirrhotic MASH with F2–F3 fibrosis. Japanese ESSENCE subgroup participants received once-weekly semaglutide 2.4 mg or placebo.

Monitoring & Follow-up

• The article states that extended follow-up is needed to determine whether semaglutide lowers the risk of liver-related events.

Risks

• The Japanese subgroup and BMI- and age-stratified analyses were small; the stratified analyses were exploratory.

• The lowest BMI stratum assessed was <27 kg/m², so efficacy in non-obese individuals with BMI <25 kg/m² has not been established.

• Fibrosis improvement was reported in 36.5% with semaglutide and 28.9% with placebo; the treatment difference was imprecise in the context of a relatively high placebo response and small sample size.

Patient & Prescribing Data

The first 800 randomized ESSENCE participants included 116 Japanese patients: 78 assigned to semaglutide and 38 to placebo. Japanese participants had a mean BMI of 29.8 kg/m²; 21.8% had BMI <25 kg/m², and 44.9% were aged ≥65 years.

With semaglutide, 63.1% achieved MASH resolution without fibrosis worsening and 36.5% had fibrosis improvement without worsening steatohepatitis; the corresponding placebo rate for fibrosis improvement was 28.9%. The safety profile was broadly consistent with the global trial. The article does not provide detailed adverse-event rates.

Clinical Best Practices

• The article notes that the Japanese subgroup was small and BMI- and age-stratified analyses were exploratory.

• The article states that efficacy in patients with BMI <25 kg/m² has not been established because the lowest assessed BMI category was <27 kg/m².

• The reported outcomes include histologic and noninvasive assessments; the article states that longer follow-up is needed to assess liver-related events.

• The article describes proposed direct hepatic mechanisms as experimental findings in mice that have not been confirmed in humans.

Related Resources & Content

1. Nakajima et al., Journal of Gastroenterology, 2026 — Semaglutide Administration in Japanese Individuals with Metabolic Dysfunction-Associated Steatohepatitis: Insights from the ESSENCE Trial Subgroup Analysis

2. Sanyal et al., New England Journal of Medicine, 2025 — Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

3. FDA, 2025 — Ongoing Non-malignant Hematological, Neurological, and Other Disorder Indications Accelerated Approvals

4. MDSpire News — Semaglutide Shows Potential in Liver Disease Trial

5. The New Gastroenterologist — Semaglutide Treatment Enhances Liver Histology in Patients with MASH

6. MDSpire News — Semaglutide Shows Dual Benefit in Knee OA

7. Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial

8. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

9. Ongoing Non-malignant Hematological, Neurological, and Other Disorder Indications Accelerated Approvals

10. Ongoing | Non-malignant Hematological, Neurological, and Other Disorder Indications Accelerated Approvals | FDA

11. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine

12. Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial.